Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Pharmacology & Pharmacy, Neurosciences & Neurology, Charcot-Marie-Tooth disease, HSPB1, Histone deacetylase 6, Mitochondria, Acetylated alpha-tubulin, Compound screening, ALZHEIMERS-DISEASE, MOUSE MODEL, TUBULIN ACETYLATION, MULTIPLE-MYELOMA, DOUBLE-BLIND, TRANSPORT, DEACETYLASE, TUBASTATIN, DEFICITS, COMBINATION, Acetylated α-tubulin, Charcot–Marie–Tooth disease, Animals, Axonal Transport, Charcot-Marie-Tooth Disease, Drug Evaluation, Preclinical, Ganglia, Spinal, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Hydroxamic Acids, Mice, Muscle, Skeletal, Neuromuscular Junction, Neurons, Pyrimidines, Tumor Cells, Cultured, 1109 Neurosciences, 1115 Pharmacology and Pharmaceutical Sciences, 1117 Public Health and Health Services, Neurology & Neurosurgery, 3209 Neurosciences, 3214 Pharmacology and pharmaceutical sciences, 5202 Biological psychology

Abstract:

Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, with an estimated prevalence of 1 in 2500. The degeneration of motor and sensory nerve axons leads to motor and sensory symptoms that progress over time and have an important impact on the daily life of these patients. Currently, there is no curative treatment available. Recently, we identified histone deacetylase 6 (HDAC6), which deacetylates α-tubulin, as a potential therapeutic target in axonal CMT (CMT2). Pharmacological inhibition of the deacetylating function of HDAC6 reversed the motor and sensory deficits in a mouse model for mutant "small heat shock protein B1" (HSPB1)-induced CMT2 at the behavioral and electrophysiological level. In order to translate this potential therapeutic strategy into a clinical application, small drug-like molecules that are potent and selective HDAC6 inhibitors are essential. To screen for these, we developed a method that consisted of 3 distinct phases and that was based on the pathological findings in the mutant HSPB1-induced CMT2 mouse model. Three different inhibitors (ACY-738, ACY-775, and ACY-1215) were tested and demonstrated to be both potent and selective HDAC6 inhibitors. Moreover, these inhibitors increased the innervation of the neuromuscular junctions in the gastrocnemius muscle and improved the motor and sensory nerve conduction, confirming that HDAC6 inhibition is a potential therapeutic strategy in CMT2. Furthermore, ACY-1215 is an interesting lead molecule as it is currently tested in clinical trials for cancer. Taken together, these results may speed up the translation of pharmacological inhibition of HDAC6 into a therapy against CMT2.